Clinical Trial Update: Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating drug-drug interaction between migalastat hydrochloride (AT1001) and agalsidase in Fabry disease completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Agalsidase (agalsidase)
• Migalastat hydrochloride (migalastat hydrochloride)

Snippet

Sponsor: Amicus Therapeutics | Conditions: Fabry Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-11-01